Preclinical Development – Biomolecular
2019 PharmSci 360
The development of efficient siRNA nanocarriers for systemic delivery represents an important goal in MDR cancer therapy. Carbonate apatite (CA) nano carrier made of carbonate and phosphate possess both anion- and cation-binding domains, to bind with negatively charged siRNA. PEG enhanced CA was synthesized using one more organic material that has tumor targetability. The average diameter of the particles was determined by Zetasizer and microscopically. The stronger binding affinity and significant cellular uptake of the siRNA were observed by quantifying fluorescence intensity. Cancer cell viability was assessed by MTT. CA with different siRNAs targeting specific genes was used to treat different breast cancer cells to suppress the expression of the proteins and evaluate their potential as therapeutic targets. Hence, hybrid CA nanoparticles have significantly (P<0.05) enhanced cytotoxicity in cancer cell lines and was also found to elucidate their roles in regulating biodistribution and breast tumour targetability in animal model studies.